{
    "hands_on_practices": [
        {
            "introduction": "The clinical management of rotavirus gastroenteritis hinges on the prompt and accurate correction of dehydration. This exercise grounds theoretical knowledge in practical application by requiring the calculation of fluid requirements for a dehydrated child. Mastering this skill  is essential, as it involves applying the Holliday-Segar method for maintenance needs alongside deficit replacement, a foundational competency in pediatric emergency medicine and infectious disease management.",
            "id": "4688710",
            "problem": "A child with acute rotavirus gastroenteritis presents with clinical signs consistent with isotonic dehydration. Assume the following scientifically grounded facts: rotavirus causes secretory diarrhea with primarily extracellular fluid loss; percent dehydration quantifies the fraction of baseline body mass lost as water; and the density of water is approximately $1\\ \\mathrm{kg}/\\mathrm{L}$ over physiologic temperature ranges. Consider a $10\\ \\mathrm{kg}$ toddler assessed to have $0.08$ dehydration. Using the Holliday-Segar method for physiologic maintenance needs and replacing the entire fluid deficit evenly over $4\\ \\mathrm{h}$, compute the maintenance fluid volume required over $4\\ \\mathrm{h}$ and the deficit fluid volume to be administered over $4\\ \\mathrm{h}$. Ignore ongoing losses and insensible variation beyond the Holliday-Segar estimate, and assume isotonic crystalloid is used for deficit replacement. Express both volumes in $\\mathrm{mL}$ and round each to four significant figures.",
            "solution": "The problem requires the calculation of two distinct fluid volumes for a pediatric patient with acute gastroenteritis: the maintenance fluid volume over a $4$-hour period and the fluid deficit volume to be replaced over the same period. We will address each calculation separately based on the provided data and clinical standards.\n\nFirst, we calculate the fluid deficit volume. The patient is a toddler with a current body mass of $W = 10 \\ \\mathrm{kg}$. The clinical assessment indicates a dehydration level of $d = 0.08$, which represents $8\\%$. The problem statement specifies that \"percent dehydration quantifies the fraction of baseline body mass lost as water\". However, in a clinical setting where the pre-illness (baseline) weight is typically unknown, the fluid deficit is pragmatically estimated based on the current (dehydrated) weight. We will follow this standard clinical interpretation.\n\nThe mass of the fluid deficit, $M_{deficit}$, is calculated as the product of the dehydration fraction $d$ and the current body mass $W$:\n$$M_{deficit} = d \\times W = 0.08 \\times 10 \\ \\mathrm{kg} = 0.8 \\ \\mathrm{kg}$$\nThe problem states that the density of water, $\\rho_{water}$, can be approximated as $1 \\ \\mathrm{kg}/\\mathrm{L}$. The volume of the fluid deficit, $V_{deficit}$, is the deficit mass divided by this density:\n$$V_{deficit} = \\frac{M_{deficit}}{\\rho_{water}} = \\frac{0.8 \\ \\mathrm{kg}}{1 \\ \\mathrm{kg}/\\mathrm{L}} = 0.8 \\ \\mathrm{L}$$\nTo express this volume in milliliters ($\\mathrm{mL}$), we use the conversion factor $1 \\ \\mathrm{L} = 1000 \\ \\mathrm{mL}$:\n$$V_{deficit} = 0.8 \\ \\mathrm{L} \\times 1000 \\ \\frac{\\mathrm{mL}}{\\mathrm{L}} = 800 \\ \\mathrm{mL}$$\nThe problem specifies that this entire deficit is to be replaced over a $4 \\ \\mathrm{h}$ period. Thus, the deficit fluid volume to be administered over $4 \\ \\mathrm{h}$ is $800 \\ \\mathrm{mL}$. Rounding this value to four significant figures gives $800.0 \\ \\mathrm{mL}$.\n\nSecond, we calculate the maintenance fluid volume using the Holliday-Segar method. This method provides the total daily ($24 \\ \\mathrm{h}$) physiological fluid requirement based on body mass. The formula is applied in tiers:\n- For the first $10 \\ \\mathrm{kg}$ of body mass: $100 \\ \\mathrm{mL}/\\mathrm{kg}/\\mathrm{day}$.\n- For the next $10 \\ \\mathrm{kg}$ (from $10.1$ to $20 \\ \\mathrm{kg}$): $50 \\ \\mathrm{mL}/\\mathrm{kg}/\\mathrm{day}$.\n- For each kilogram above $20 \\ \\mathrm{kg}$: $20 \\ \\mathrm{mL}/\\mathrm{kg}/\\mathrm{day}$.\n\nThe patient's mass is $W = 10 \\ \\mathrm{kg}$, which falls entirely within the first tier of the formula. The daily maintenance fluid volume, $V_{maint, 24h}$, is therefore:\n$$V_{maint, 24h} = 100 \\ \\frac{\\mathrm{mL}}{\\mathrm{kg} \\cdot \\mathrm{day}} \\times 10 \\ \\mathrm{kg} = 1000 \\ \\frac{\\mathrm{mL}}{\\mathrm{day}}$$\nThe problem asks for the maintenance volume required over a time period of $t = 4 \\ \\mathrm{h}$. To find this, we calculate the volume for this fraction of a day. The fraction is $\\frac{4 \\ \\mathrm{h}}{24 \\ \\mathrm{h}} = \\frac{1}{6}$.\nThe maintenance volume over $4 \\ \\mathrm{h}$, $V_{maint, 4h}$, is:\n$$V_{maint, 4h} = V_{maint, 24h} \\times \\frac{t}{24 \\ \\mathrm{h}} = 1000 \\ \\mathrm{mL} \\times \\frac{4}{24} = 1000 \\ \\mathrm{mL} \\times \\frac{1}{6}$$\n$$V_{maint, 4h} = \\frac{500}{3} \\ \\mathrm{mL} \\approx 166.666... \\ \\mathrm{mL}$$\nRounding this result to four significant figures yields $166.7 \\ \\mathrm{mL}$.\n\nThe two required volumes are the $4$-hour maintenance volume and the $4$-hour deficit replacement volume.\nMaintenance volume over $4 \\ \\mathrm{h}$: $166.7 \\ \\mathrm{mL}$.\nDeficit volume over $4 \\ \\mathrm{h}$: $800.0 \\ \\mathrm{mL}$.",
            "answer": "$$\\boxed{\\begin{pmatrix} 166.7  800.0 \\end{pmatrix}}$$"
        },
        {
            "introduction": "The widespread use of live oral rotavirus vaccines represents a major public health victory, but it also creates a complex diagnostic dilemma: distinguishing transient vaccine virus shedding from a true wild-type infection. This practice challenges you to act as a clinical consultant, developing an interpretive framework that synthesizes temporal, quantitative, and genetic data from modern laboratory tests. Solving this problem  hones the critical reasoning skills needed to navigate the nuances of post-vaccination surveillance and patient care.",
            "id": "4688764",
            "problem": "A pediatric infectious disease fellow is asked to design an interpretive framework for rotavirus-positive stool results in infants who recently received a live oral rotavirus vaccine. The task is to specify rules that minimize misclassification of vaccine virus shedding as wild-type rotavirus infection and vice versa. The setting includes infants receiving either the monovalent human strain vaccine Rotarix (also termed Rotavirus Vaccine $1$, $\\mathrm{RV1}$) or the pentavalent bovine-human reassortant vaccine RotaTeq (also termed Rotavirus Vaccine $5$, $\\mathrm{RV5}$). The fellow must account for commonly used diagnostics: enzyme immunoassay (EIA) for group A rotavirus antigen and quantitative reverse transcription polymerase chain reaction (qRT-PCR), reported as a cycle threshold ($C_t$), along with genotyping based on viral protein $7$ (VP7, yielding $G$ types) and viral protein $4$ (VP4, yielding $P$ types) and, when available, backbone markers (for example, nonstructural protein segments linked to the bovine WC3 backbone in $\\mathrm{RV5}$ reassortants).\n\nUse the following fundamental base to reason from first principles:\n- Live attenuated oral vaccines replicate in the gut mucosa to induce local immunity; replication is constrained by attenuation and host immunity and leads to shedding in stool for a limited window following administration.\n- EIA detects group A rotavirus antigen (major capsid protein VP6) but does not discriminate vaccine strains from wild-type strains.\n- In qRT-PCR, the cycle threshold $C_t$ is inversely related to the logarithm of the template copy number; lower $C_t$ generally indicates higher viral RNA concentration in the sample.\n- Genotype assignment by VP7 ($G$) and VP4 ($P$) can match known vaccine strain signatures or wild-type epidemiologic patterns; $\\mathrm{RV1}$ is derived from a human $G1P[8]$ strain, and $\\mathrm{RV5}$ contains bovine-human reassortants covering $G1$–$G4$ and $P[8]$ with a bovine WC3 backbone that can be recognized by segment-specific assays or sequencing.\n\nLet $t$ denote the days since vaccination, let $C_t$ denote the qRT-PCR cycle threshold, and let $G$/$P$ denote the VP7/VP4 genotype, with optional backbone markers when available. The fellow must propose rules that, when applied to symptomatic infants with rotavirus-positive stools, help distinguish vaccine virus shedding from wild-type infection using $t$, $C_t$, and genotype/backbone information. Which option below provides the most defensible and scientifically grounded rule set?\n\nA. Classify all EIA-positive stools collected at $t \\leq 2$ days post-vaccination as vaccine shedding, and all EIA-positive stools collected at $t  2$ days as wild-type infection; do not incorporate $C_t$ or genotype because antigen positivity sufficiently indicates rotavirus presence.\n\nB. Use a single qRT-PCR threshold: if $C_t  35$, call the result vaccine shedding; if $C_t \\leq 35$, call the result wild-type infection; time since vaccination and genotype are not needed because $C_t$ captures viral load differences.\n\nC. Integrate $t$, $C_t$, and genotype/backbone markers: classify as probable vaccine shedding when $t \\leq 14$ days, $C_t$ is high (for example, $C_t \\geq 30$), and $G$/$P$ with backbone markers match the administered vaccine (for example, $\\mathrm{RV1}$-like $G1P[8]$ without nonhuman segments, versus $\\mathrm{RV5}$-like reassortant patterns with WC3 backbone markers). Classify as probable wild-type infection when $t  14$ days and/or $C_t$ is low (for example, $C_t \\leq 25$) and genotyping does not match vaccine strain signatures (for example, $G2P[4]$ in circulation without vaccine backbone). In discordant cases (for example, $t \\leq 14$ days with low $C_t$ or severe symptoms), escalate to full-segment sequencing and clinical correlation, including host immune status.\n\nD. Base classification solely on symptom severity: if the infant has severe dehydration and a high Vesikari score, call wild-type infection; if mild or no symptoms, call vaccine shedding, regardless of $t$, $C_t$, or genotype.\n\nE. Exclude all rotavirus-positive results within $t \\leq 60$ days of vaccination as uninterpretable and defer classification entirely; classify only results with $t  60$ days as wild-type infection.\n\nSelect the single best option.",
            "solution": "The problem statement is a valid exercise in clinical and diagnostic reasoning in the field of pediatric infectious diseases. It is scientifically grounded, well-posed, objective, and contains sufficient information to evaluate the proposed interpretive frameworks.\n\nThe task is to devise a set of rules to distinguish between rotavirus shedding from a live oral vaccine and infection by a wild-type rotavirus strain in a symptomatic infant. A robust framework must integrate all available, relevant data streams to maximize accuracy and minimize misclassification. The key data types are the time since vaccination ($t$), viral load as indicated by the quantitative reverse transcription polymerase chain reaction (qRT-PCR) cycle threshold ($C_t$), and viral genotyping ($G$/$P$ types and backbone markers).\n\nLet us analyze the contribution of each data type based on the provided first principles:\n1.  **Time since vaccination ($t$):** Live attenuated vaccine viruses replicate in the gut and are shed in the stool primarily for a limited period after administration. While shedding can be detected for several weeks, it is most frequent and intense in the first $1$ to $2$ weeks. Thus, a small value of $t$ increases the prior probability that a detected rotavirus is of vaccine origin. However, a coincidental wild-type infection can occur at any time, including shortly after vaccination.\n2.  **Viral load ($C_t$):** The $C_t$ value is inversely proportional to the logarithm of the viral RNA concentration. Wild-type infections typically cause symptomatic disease through vigorous viral replication, leading to high viral loads (and thus low $C_t$ values, often $C_t \\leq 25$). Vaccine virus replication is attenuated, generally resulting in lower viral loads (and thus higher $C_t$ values, e.g., $C_t \\geq 30$). However, there can be an overlap in the distribution of $C_t$ values, and this metric alone is not perfectly discriminatory.\n3.  **Genotype and Backbone Markers:** This is the most definitive evidence. The genotype of the detected virus can be directly compared to the known composition of the administered vaccine.\n    - The monovalent vaccine, $\\mathrm{RV1}$, is derived from a human $G1P[8]$ strain.\n    - The pentavalent vaccine, $\\mathrm{RV5}$, consists of five bovine-human reassortant viruses with a characteristic bovine (WC3 strain) genetic backbone. These reassortants express human rotavirus outer capsid proteins for the genotypes $G1$, $G2$, $G3$, $G4$, and $P[8]$.\n    - Detection of a virus with a genotype matching the vaccine (e.g., $G1P[8]$ for $\\mathrm{RV1}$; a $G1$, $G2$, $G3$, $G4$, or $P[8]$ type with a WC3 backbone for $\\mathrm{RV5}$) strongly suggests a vaccine-derived strain. Conversely, detection of a non-vaccine genotype (e.g., $G2P[4]$, a common wild-type strain) or a vaccine-like genotype lacking the specific vaccine backbone (e.g., a $G1P[8]$ strain in an $\\mathrm{RV5}$ recipient that lacks WC3 markers) is strong evidence of a wild-type infection.\n\nA comprehensive and scientifically defensible framework must therefore synthesize all three pieces of information ($t$, $C_t$, and genotype) and include provisions for ambiguous or discordant results.\n\n**Evaluation of Options:**\n\n**A. Classify all EIA-positive stools collected at $t \\leq 2$ days post-vaccination as vaccine shedding, and all EIA-positive stools collected at $t  2$ days as wild-type infection; do not incorporate $C_t$ or genotype because antigen positivity sufficiently indicates rotavirus presence.**\nThis option is fundamentally flawed. The time cutoff of $t=2$ days is biologically incorrect; peak vaccine virus shedding occurs later, typically around day $7$. It also ignores the possibility of a coincidental wild-type infection occurring within $2$ days of vaccination. Furthermore, it completely discards the most powerful discriminatory data: viral load ($C_t$) and, most importantly, genotype. The premise states correctly that the enzyme immunoassay (EIA) is non-discriminatory. Relying on it alone after establishing a simple, arbitrary time cutoff is an invalid approach.\n**Verdict: Incorrect.**\n\n**B. Use a single qRT-PCR threshold: if $C_t  35$, call the result vaccine shedding; if $C_t \\leq 35$, call the result wild-type infection; time since vaccination and genotype are not needed because $C_t$ captures viral load differences.**\nThis option improperly relies on a single, arbitrary data point. While $C_t$ reflects viral load, there is significant overlap between the loads seen in vaccine shedding and wild-type infections. A true wild-type infection can present with a high $C_t$ (low load) early or late in the course of illness, and some individuals (e.g., immunocompromised) may shed vaccine virus at high loads (low $C_t$). Ignoring the time since vaccination ($t$) and the definitive evidence from genotyping is scientifically unsound and will lead to frequent misclassification.\n**Verdict: Incorrect.**\n\n**C. Integrate $t$, $C_t$, and genotype/backbone markers: classify as probable vaccine shedding when $t \\leq 14$ days, $C_t$ is high (for example, $C_t \\geq 30$), and $G$/$P$ with backbone markers match the administered vaccine (for example, $\\mathrm{RV1}$-like $G1P[8]$ without nonhuman segments, versus $\\mathrm{RV5}$-like reassortant patterns with WC3 backbone markers). Classify as probable wild-type infection when $t  14$ days and/or $C_t$ is low (for example, $C_t \\leq 25$) and genotyping does not match vaccine strain signatures (for example, $G2P[4]$ in circulation without vaccine backbone). In discordant cases (for example, $t \\leq 14$ days with low $C_t$ or severe symptoms), escalate to full-segment sequencing and clinical correlation, including host immune status.**\nThis option presents a comprehensive, multi-factorial algorithm that correctly synthesizes all available evidence. It defines reasonable, evidence-based criteria for probable vaccine shedding (recent vaccination, low viral load, matching genotype) and probable wild-type infection (later time point, high viral load, or non-matching genotype). Crucially, it acknowledges the existence of ambiguous or discordant cases and proposes a scientifically appropriate escalation pathway: advanced molecular testing (full-segment sequencing) and integration with the full clinical picture. This represents best practice in modern clinical microbiology and infectious disease diagnostics.\n**Verdict: Correct.**\n\n**D. Base classification solely on symptom severity: if the infant has severe dehydration and a high Vesikari score, call wild-type infection; if mild or no symptoms, call vaccine shedding, regardless of $t$, $C_t$, or genotype.**\nThis option wrongly prioritizes subjective clinical signs over objective laboratory data. While wild-type infections are generally more severe, live attenuated rotavirus vaccines can cause symptomatic gastroenteritis in a subset of infants. Conversely, wild-type infections can be mild or even asymptomatic. Disregarding definitive laboratory markers like genotype is a major flaw that would lead to significant misclassification based on the variable host response to infection.\n**Verdict: Incorrect.**\n\n**E. Exclude all rotavirus-positive results within $t \\leq 60$ days of vaccination as uninterpretable and defer classification entirely; classify only results with $t  60$ days as wild-type infection.**\nThis approach is excessively cautious to the point of being clinically useless. It fails the primary task, which is to create an *interpretive framework*, not to avoid interpretation. A $60$-day window is far longer than the typical period of significant vaccine shedding. This rule would cause a large number of true wild-type infections occurring within two months of vaccination to be missed or mismanaged, which has negative consequences for both patient care and public health surveillance. It ignores the power of molecular diagnostics ($C_t$, genotyping) to resolve most cases long before $60$ days have passed.\n**Verdict: Incorrect.**",
            "answer": "$$\\boxed{C}$$"
        },
        {
            "introduction": "Beyond individual patient care, a core task in infectious disease is to measure the population-level impact of interventions like vaccination. This exercise guides you through the process of calculating vaccine effectiveness from the results of a prospective cohort study, a fundamental method in epidemiology. By deriving the point estimate and confidence intervals for vaccine effectiveness , you will practice the quantitative skills necessary to evaluate public health programs and communicate their value with scientific rigor.",
            "id": "4688731",
            "problem": "A public health team conducts a prospective cohort study across a network of pediatric clinics during a single rotavirus season to estimate the protection conferred by routine infant rotavirus immunization against laboratory-confirmed rotavirus gastroenteritis among children aged $6$–$24$ months. Children are classified by vaccination status at the start of the season and followed for clinically significant acute watery diarrhea; stool specimens from all diarrhea episodes are tested by polymerase chain reaction (PCR) for rotavirus. Assume negligible loss to follow-up, independent outcomes, equal follow-up duration across groups, and no misclassification of exposure or outcome.\n\nData summary:\n- Vaccinated cohort: $n_{v} = 1800$ children; rotavirus-positive diarrhea cases $a = 54$.\n- Unvaccinated cohort: $n_{u} = 600$ children; rotavirus-positive diarrhea cases $c = 96$.\n\nUsing only foundational definitions relevant to cohort studies in infectious diseases epidemiology:\n1. Starting from the definition of risk (attack rate) and the interpretation of vaccine effectiveness (VE) as the proportional reduction in risk among vaccinated individuals relative to unvaccinated individuals, derive an explicit expression for the vaccine effectiveness in terms of the attack rates among vaccinated and unvaccinated cohorts.\n2. Compute the point estimate of the vaccine effectiveness for this study.\n3. Using a logarithm-based normal approximation to the sampling distribution of the estimated risk ratio (RR), construct a two-sided $95$ percent confidence interval (CI) for the risk ratio and then transform it to a confidence interval for the vaccine effectiveness. State any distributional approximations you invoke.\n4. Finally, report the lower bound of the $95$ percent confidence interval for the vaccine effectiveness as a decimal (do not use a percent sign), rounded to four significant figures.",
            "solution": "The problem statement is evaluated as valid. It presents a standard epidemiological problem with a self-contained, consistent, and scientifically grounded data set. The objectives are clear and the methods specified are appropriate for the data provided. There are no contradictions, ambiguities, or violations of scientific principles.\n\nThe solution proceeds in four parts as requested.\n\n1. Derivation of the expression for Vaccine Effectiveness (VE).\n\nThe risk, or attack rate ($AR$), is the probability of developing a disease over a specified period. For the vaccinated and unvaccinated cohorts, the risks are defined as:\nRisk in vaccinated cohort: $AR_v = \\frac{\\text{cases in vaccinated}}{\\text{total vaccinated}} = \\frac{a}{n_v}$\nRisk in unvaccinated cohort: $AR_u = \\frac{\\text{cases in unvaccinated}}{\\text{total unvaccinated}} = \\frac{c}{n_u}$\n\nVaccine effectiveness (VE) is defined as the proportional reduction in risk among the vaccinated group relative to the risk in the unvaccinated group. This can be expressed as the difference in risk, divided by the risk in the unvaccinated (baseline) group:\n$$VE = \\frac{AR_u - AR_v}{AR_u}$$\nThis expression can be simplified:\n$$VE = \\frac{AR_u}{AR_u} - \\frac{AR_v}{AR_u} = 1 - \\frac{AR_v}{AR_u}$$\nThe quantity $\\frac{AR_v}{AR_u}$ is the definition of the Risk Ratio ($RR$). Therefore, the relationship between vaccine effectiveness and the risk ratio is:\n$$VE = 1 - RR$$\n\n2. Computation of the point estimate of Vaccine Effectiveness.\n\nGiven the data:\n- Vaccinated cohort: $n_v = 1800$ children, with $a = 54$ cases.\n- Unvaccinated cohort: $n_u = 600$ children, with $c = 96$ cases.\n\nFirst, we compute the point estimates of the attack rates for each cohort. The hat symbol ($\\hat{\\cdot}$) denotes a point estimate from the sample data.\n$$\\hat{AR}_v = \\frac{a}{n_v} = \\frac{54}{1800} = 0.03$$\n$$\\hat{AR}_u = \\frac{c}{n_u} = \\frac{96}{600} = 0.16$$\nNext, we compute the point estimate of the risk ratio ($\\hat{RR}$):\n$$\\hat{RR} = \\frac{\\hat{AR}_v}{\\hat{AR}_u} = \\frac{0.03}{0.16} = 0.1875$$\nFinally, we compute the point estimate of the vaccine effectiveness ($\\hat{VE}$):\n$$\\hat{VE} = 1 - \\hat{RR} = 1 - 0.1875 = 0.8125$$\nThe point estimate for the vaccine effectiveness is $81.25\\%$.\n\n3. Construction of the $95\\%$ confidence interval (CI) for Vaccine Effectiveness.\n\nThe problem requires using a logarithm-based normal approximation. We first construct a CI for the natural logarithm of the risk ratio, $\\ln(RR)$, and then transform it back to a CI for $RR$ and subsequently for $VE$.\n\nThe sampling distribution of $\\ln(\\hat{RR})$ is assumed to be approximately normal. The estimated variance of $\\ln(\\hat{RR})$ is given by:\n$$ \\hat{Var}(\\ln(\\hat{RR})) = \\frac{1-\\hat{AR}_v}{a} + \\frac{1-\\hat{AR}_u}{c} = \\frac{n_v-a}{a \\cdot n_v} + \\frac{n_u-c}{c \\cdot n_u} $$\nSubstituting the given values:\n$$ \\hat{Var}(\\ln(\\hat{RR})) = \\frac{1800-54}{54 \\cdot 1800} + \\frac{600-96}{96 \\cdot 600} = \\frac{1746}{97200} + \\frac{504}{57600} $$\n$$ \\hat{Var}(\\ln(\\hat{RR})) \\approx 0.01796296 + 0.00875 \\approx 0.02671296 $$\nThe standard error ($SE$) is the square root of the variance:\n$$SE(\\ln(\\hat{RR})) = \\sqrt{0.02671296} \\approx 0.163441$$\nA two-sided $95\\%$ confidence interval for $\\ln(RR)$ is constructed as $\\ln(\\hat{RR}) \\pm Z_{1-\\alpha/2} \\cdot SE(\\ln(\\hat{RR}))$. For a $95\\%$ CI, $\\alpha=0.05$, and the critical value from the standard normal distribution is $Z_{0.975} \\approx 1.96$.\nThe point estimate for $\\ln(\\hat{RR})$ is:\n$$\\ln(\\hat{RR}) = \\ln(0.1875) \\approx -1.673979$$\nThe confidence interval for $\\ln(RR)$ is:\n$$CI_{\\ln(RR)} = -1.673979 \\pm 1.96 \\cdot (0.163441)$$\n$$CI_{\\ln(RR)} = -1.673979 \\pm 0.320344$$\n$$CI_{\\ln(RR)} = [-1.994323, -1.353635]$$\nTo obtain the confidence interval for $RR$, we exponentiate the bounds:\n$$CI_{RR} = [\\exp(-1.994323), \\exp(-1.353635)]$$\n$$CI_{RR} = [0.136114, 0.258292]$$\nFinally, we transform the CI for $RR$ into a CI for $VE$ using the relationship $VE = 1 - RR$. This transformation reverses the order of the bounds:\n$$CI_{VE} = [1 - UB_{RR}, 1 - LB_{RR}]$$\nwhere $LB$ and $UB$ are the lower and upper bounds, respectively.\n$$CI_{VE} = [1 - 0.258292, 1 - 0.136114]$$\n$$CI_{VE} = [0.741708, 0.863886]$$\nThe $95\\%$ confidence interval for the vaccine effectiveness is approximately $[0.7417, 0.8639]$.\n\n4. Reporting the lower bound of the $95\\%$ CI for VE.\n\nThe lower bound of the $95\\%$ confidence interval for vaccine effectiveness is $0.741708$. Rounding to four significant figures, we get $0.7417$.",
            "answer": "$$\\boxed{0.7417}$$"
        }
    ]
}